• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Ophthalmology

Race and insurance status may affect amblyopia treatment outcomes

byMolly Munsell
September 14, 2022
in 2 Minute Medicine, Ophthalmology, Public Health
Reading Time: 2 mins read
Patient Basics: Lazy Eye (Amblyopia)
Share on FacebookShare on TwitterShare on LinkedIn

1. In a large retrospective database study, Black children with amblyopia were significantly less likely to be successfully treated based on visual acuity outcomes than White children.

2. Children aged 3-7 with Medicaid coverage were 35% less likely to have successful amblyopia therapy than children with private insurance.

Evidence Rating Level: 2 (Good)

Study Rundown: Amblyopia is poorer vision in one eye caused by abnormalities during visual development, which can include uneven refractive error or strabismus. It is treated by regular occlusion of the unaffected eye using dilating drops or patching. This study aimed to analyze demographic factors affecting outcomes in amblyopia treatment. Among nearly 19,000 children, amblyopia treatment was successful in 77.3% of those aged 3-7 and 55.5% of those aged 8-12. Black children aged 3-7 were 29% less likely to be successfully treated than White children. For children aged 8-12, Black race was also significantly associated with lower treatment success rate, but Hispanic/Latino ethnicity was associated with increased treatment success. Medicaid coverage was independently, significantly associated with lower rates of treatment success. Successful amblyopia treatment requires not only presentation and prompt initiation of therapy before neuroplasticity decreases, but also regular follow-up to assess treatment efficacy and explore treatment of underlying conditions such as strabismus or refractive error. The relative role of age at presentation compared to differences in care, such as follow-up frequency, adherence, or provider bias, are unclear from this data. Nonetheless, these disparities are highly troubling, as untreated and unsuccessfully treated amblyopia have lifelong consequences for vision and quality and life.

Click to read the study in Ophthalmology

Relevant Reading: Amblyopia and quality of life: A systematic review

RELATED REPORTS

Optogenetic therapy may partially restore vision in retinitis pigmentosa

Trends in firearm-related hospitalizations and deaths in New Zealand

In-Depth [retrospective cohort]: Children who were 3-12 years old at the time of enrollment in the national Intelligent Research in Sight (IRIS) database between 2013-2019 were included. The primary outcome, IRIS-50, has been previously studied and reflects unilateral amblyopia associated with strabismus, refractive error, or both in children with at least one follow-up visit recorded. Treatment success is defined by IRIS-50 as best corrected visual acuity difference between eyes less than 0.23 logMAR units, acuity improvement of at least 3 Snellen chart lines in the affected eye, and/or acuity of 20/30 or better in the affected eye. Multiple logistic regression models were adjusted for sex, race, ethnicity, and insurance type. For children 3-7 years old, the odds ratio for treatment success in female compared to male children was 1.01 [95% confidence interval (CI) 0.94-1.08]. The odds ratios for 3-7-year-old Black, Hispanic, and Asian children compared to White children were 0.71 (95% CI 0.62-0.83), 0.93 (0.83-1.04), and 0.97 (0.77-1.23). The odds ratio for children with Medicaid compared to private insurance was 0.65 (95% CI 0.60-0.71).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: disparitiesinsuranceLazy Eye (Amblyopia)racial disparitiesvision
Previous Post

POINT trial: Clopidogrel and Aspirin for Acute Ischemic Stroke [Classics Series]

Next Post

The OVIVA trial: Oral versus intravenous antibiotics for bone and joint infection [Classics Series]

RelatedReports

A woman using a red light therapy device while seated, surrounded by workout equipment and papers, suggesting engagement in wellness practices.
Chronic Disease

Optogenetic therapy may partially restore vision in retinitis pigmentosa

October 23, 2026
Steroids and opioids often inappropriately prescribed in the emergency department for pediatric pneumonia and sinusitis
Public Health

Trends in firearm-related hospitalizations and deaths in New Zealand

September 22, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Fibroids, Fatigue, Tainted Syrups, and Bariatric Barriers

August 5, 2025
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Chronic Disease

Personalized visual perceptual learning digital therapy may improve vision post-stroke

May 30, 2025
Next Post
ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]

The OVIVA trial: Oral versus intravenous antibiotics for bone and joint infection [Classics Series]

Long-term outcomes for off-pump and on-pump CABG are similar

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

Significant amount of unhealthy children’s foods marketed to parents

Artificial sweetener intake and association with cardiovascular disease risk

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An electronic health record tool for exercise prescription may reduce fall rate among older adults
  • Optogenetic therapy may partially restore vision in retinitis pigmentosa
  • An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.